Do you have cancer that has a PIK3CA Mutation?

If so, consider the ReDiscover Study, a clinical trial for individuals with metastatic cancer who have a PIK3CA mutation.

Study participation may help offer insight into the safety and activity of a mutant selective PI3KCA inhibitor in patients with PI3KCA mutant tumors.